Dermata Therapeutics, Inc. (DRMA): auditor change — Dermata Therapeutics changes auditor to Baker Tilly after Moss Adams merger

Dermata Therapeutics, Inc.

Moss Adams merged into Baker Tilly US, LLP effective June 3, 2025; audit committee approved Baker Tilly as successor.
No disagreements with Moss Adams on accounting principles or audit scope for FY2024, FY2023, or interim period.
Prior audit reports included a going concern uncertainty paragraph; no adverse or modified opinions.
Moss Adams provided a letter agreeing with the statements, filed as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

Dermata Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.

Action: engagement
Auditor: Baker Tilly US, LLP

Exact text from the filing

In connection with the notification of the merger, the audit committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.

View on SEC.gov

Browse all auditor changes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-013823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.